Sections
- Alternative Therapies
- Blood, Heart and Circulation
- Bones and Muscles
- Brain and Nerves
- Cancers
- Child health
- Cosmetic Surgery
- Digestive System
- Disorders and Conditions
- Drugs Approvals and Trials
- Environmental Health
- Ear, Nose and Throat
- Eyes and Vision
- Female Reproductive
- Genetics and Birth Defects
- Geriatrics and Aging
- Immune System
- Infections
- Kidneys and Urinary System
- Life style and Fitness
- Lungs and Breathing
- Male Reproductive
- Medical Breakthroughs
- Mental Health and Behavior
- Metabolic Problems
- Oral and Dental Health
- Pregnancy and Childbirth
- Public Health and Safety
- Skin, Hair and Nails
- Substance Abuse
- Surgery and Rehabilitation
Research at UMDNJ Identifies How Vitamin D Combats MS
While for years scientists have noted an association between levels of vitamin D in a person’s body and the person’s ability to resist or minimize the effects of multiple sclerosis (MS), the mechanism involved has not been established. However new research by Sylvia Christakos, Ph.D., of UMDNJ-New Jersey Medical School (principal investigator) Sneha Joshi (first author, a UMDNJ Ph.D. student), and colleagues (including co-investigator Lawrence Steinman, MD, of Stanford University) appears to have uncovered that process.
The study, published in the journal Molecular and Cellular Biology, finds that vitamin D directly terminates the production of a disease-causing protein.
During MS (“EAE” in mice), a damaging protein called interleukin-17 (IL-17) is produced by immune cells in the brain. The investigators, a collaborative team of scientists from the University of Medicine and Dentistry of New Jersey and Stanford University, find that after vitamin D binds to its receptor, the receptor parks itself on the gene that encodes IL-17. By doing so, the receptor occupies a site normally reserved for a protein called NFAT, which is required to turn the gene on. The gene stays off and IL-17 levels plummet.
At the same time, the vitamin D receptor turns on another gene, whose product generates suppressive T cells that combat the destructive action of their IL-17-producing counterparts.
According to the researchers, the mechanism they identify suggests what might be a new path toward pharmaceutical treatment of MS, as well as therapies for other autoimmune diseases that might include rheumatoid arthritis, type 1 diabetes, eczema and psoriasis.
Journalists interested in interviewing Sylvia Christakos, Ph.D., should contact Rob Forman, UMDNJ Chief of News Services, at 973-972-7276 or formanra@umdnj.edu.
The University of Medicine and Dentistry of New Jersey (UMDNJ) is the nation's largest free-standing public health sciences university with more than 6,000 students attending the state's three medical schools, its only dental school, a graduate school of biomedical sciences, a school of health related professions, a school of nursing and its only school of public health on five campuses. UMDNJ operates University Hospital, a Level I Trauma Center in Newark, and University Behavioral HealthCare, which provides a continuum of healthcare services with multiple locations throughout the state.

Post your comment